A Randomized, Open-Label, International, Multi-Center, Phase 3 Clinical Study of PD-1 Antibody SHR-1210 Plus Apatinib Mesylate Versus Sorafenib as First-Line Therapy in Patients With Advanced Hepatocellular Carcinoma (HCC) Who Have Not Previously Received Systemic Therapy
Phase of Trial: Phase III
Latest Information Update: 04 Dec 2019
Price : $35 *
At a glance
- Drugs Camrelizumab (Primary) ; Rivoceranib (Primary) ; Sorafenib
- Indications Liver cancer
- Focus Registrational; Therapeutic Use
- Sponsors Jiangsu Hengrui Medicine Co.
- 01 Dec 2019 Planned End Date changed from 1 Jan 2022 to 1 Jun 2022.
- 01 Dec 2019 Planned primary completion date changed from 1 Jul 2021 to 1 Dec 2021.
- 25 Dec 2018 Planned number of patients changed from 504 to 510.